- |||||||||| LY3143921 / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov) - Oct 18, 2023
P1, N=69, Active, not recruiting,
Trial completion date: Jul 2023 --> Feb 2027 | Trial primary completion date: Jul 2023 --> Feb 2027
- |||||||||| LY3143921 / Eli Lilly
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases: CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov) - Jul 27, 2022
P1, N=69, Active, not recruiting,
Trial completion date: Jul 2023 --> Feb 2027 | Trial primary completion date: Jul 2023 --> Feb 2027 Recruiting --> Active, not recruiting | N=115 --> 69 | Trial completion date: Jan 2022 --> Jul 2023 | Trial primary completion date: Jan 2022 --> Jul 2023
- |||||||||| LY3143921 / Eli Lilly
Enrollment change, Metastases: CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov) - Aug 20, 2021
P1, N=115, Recruiting,
Significant monotherapy clinical activity was not observed; further analyses should investigate potential predictive response biomarkers and rational combination approaches. N=68 --> 115
- |||||||||| LY3143921 / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov) - Jun 25, 2020
P1, N=68, Recruiting,
N=68 --> 115 Trial completion date: Nov 2020 --> Jan 2022 | Trial primary completion date: Nov 2020 --> Jan 2022
- |||||||||| LY3143921 / Eli Lilly
Enrollment open, Metastases: CRUKD/17/004: A CR-UK Phase I Trial of LY3143921 (clinicaltrials.gov) - Jun 12, 2017
P1, N=68, Recruiting,
The pharmacokinetic data generated to date are consistent with dose dependent increases in drug exposure observed with a flat dosing regimen for LY3143921 hydrate. Not yet recruiting --> Recruiting
|
